Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV grew its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.3% during the 1st quarter, Holdings Channel reports. The firm owned 18,952 shares of the medical equipment provider’s stock after buying an additional 56 shares during the period. Intuitive Surgical comprises approximately 0.9% of Azzad Asset Management Inc. ADV’s investment portfolio, making the stock its 13th biggest holding. Azzad Asset Management Inc. ADV’s holdings in Intuitive Surgical were worth $7,564,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the business. Norges Bank purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $1,313,238,000. WCM Investment Management LLC purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $575,536,000. International Assets Investment Management LLC lifted its stake in shares of Intuitive Surgical by 32,360.5% during the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after buying an additional 684,749 shares during the period. Alphinity Investment Management Pty Ltd raised its stake in Intuitive Surgical by 113.2% during the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock worth $430,525,000 after purchasing an additional 677,455 shares during the period. Finally, Coatue Management LLC raised its stake in Intuitive Surgical by 65.7% during the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock worth $439,106,000 after purchasing an additional 516,054 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

ISRG traded down $5.81 during trading hours on Wednesday, reaching $433.00. 203,652 shares of the stock traded hands, compared to its average volume of 1,514,258. The firm’s fifty day simple moving average is $406.41 and its two-hundred day simple moving average is $385.08. The company has a market cap of $153.59 billion, a price-to-earnings ratio of 78.55, a PEG ratio of 5.75 and a beta of 1.39. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $448.10.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business’s revenue was up 11.5% on a year-over-year basis. During the same period last year, the business earned $1.00 EPS. On average, research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Mark Brosius sold 175 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the transaction, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The disclosure for this sale can be found here. In the last three months, insiders sold 17,956 shares of company stock valued at $6,927,011. Corporate insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of a number of recent analyst reports. Citigroup increased their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Piper Sandler increased their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 price target on the stock. Jefferies Financial Group increased their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Finally, BTIG Research increased their price target on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $404.79.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.